CA1234106A - COMPOUNDS HAVING ANTIINFLAMMATORY ACTIVITY, OBTAINED BY COMPLEXATION WITH .beta.-CYCLODEXTRIN, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - Google Patents

COMPOUNDS HAVING ANTIINFLAMMATORY ACTIVITY, OBTAINED BY COMPLEXATION WITH .beta.-CYCLODEXTRIN, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Info

Publication number
CA1234106A
CA1234106A CA000474850A CA474850A CA1234106A CA 1234106 A CA1234106 A CA 1234106A CA 000474850 A CA000474850 A CA 000474850A CA 474850 A CA474850 A CA 474850A CA 1234106 A CA1234106 A CA 1234106A
Authority
CA
Canada
Prior art keywords
piroxicam
cyclodextrin
complex
beta
process according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000474850A
Other languages
English (en)
French (fr)
Inventor
Paolo Chiesi
Vittorio Servadio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Application granted granted Critical
Publication of CA1234106A publication Critical patent/CA1234106A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
CA000474850A 1984-02-22 1985-02-21 COMPOUNDS HAVING ANTIINFLAMMATORY ACTIVITY, OBTAINED BY COMPLEXATION WITH .beta.-CYCLODEXTRIN, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Expired CA1234106A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT19735/84A IT1196033B (it) 1984-02-22 1984-02-22 Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche
IT19735A/84 1984-02-22

Publications (1)

Publication Number Publication Date
CA1234106A true CA1234106A (en) 1988-03-15

Family

ID=11160778

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000474850A Expired CA1234106A (en) 1984-02-22 1985-02-21 COMPOUNDS HAVING ANTIINFLAMMATORY ACTIVITY, OBTAINED BY COMPLEXATION WITH .beta.-CYCLODEXTRIN, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Country Status (19)

Country Link
US (1) US4603123A (enExample)
EP (1) EP0153998B1 (enExample)
JP (1) JPS60208979A (enExample)
KR (1) KR870001960B1 (enExample)
AT (1) ATE52263T1 (enExample)
AU (1) AU550007B2 (enExample)
BE (1) BE900836A (enExample)
CA (1) CA1234106A (enExample)
DE (2) DE3482041D1 (enExample)
DK (1) DK164911C (enExample)
ES (1) ES536909A0 (enExample)
IE (1) IE58231B1 (enExample)
IT (1) IT1196033B (enExample)
MY (1) MY101374A (enExample)
NZ (1) NZ211114A (enExample)
PH (1) PH22075A (enExample)
PT (1) PT79997B (enExample)
SG (1) SG53690G (enExample)
ZA (1) ZA848156B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU43290B (en) * 1986-11-13 1989-06-30 Lek Tovarna Farmacevtskih Process for preparing inclusioned complex of ibuproxane with beta-cyclodextrine
IT1204725B (it) * 1987-06-17 1989-03-10 Edmond Pharma Srl Complessi di inclusione del dipiridamolo con ciclodestrine
NZ225045A (en) * 1987-07-01 1990-06-26 Janssen Pharmaceutica Nv Antiviral pharmaceutical compositions containing cyclodextrin and an antiviral agent
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
DE3809808A1 (de) * 1988-03-23 1989-10-05 Hexal Pharma Gmbh & Co Kg Feste, insbesondere festorale und rektale, etofenamat enthaltende arzneimittel
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
IT1241088B (it) * 1990-03-27 1993-12-29 Chiesi Farma Spa Procedimento per la preparazione di complessi piroxicam/ciclodestrina,prodotti ottenuti e loro composizioni farmaceutiche
US5180716A (en) * 1990-08-01 1993-01-19 The Regents Of The University Of California Cyclodextrin complexes for neuraxial administration of drugs
EP0519428B1 (en) * 1991-06-21 2000-09-20 Takeda Chemical Industries, Ltd. Cyclodextrin compositions with fumagillol derivates
US20040014695A1 (en) * 1992-06-19 2004-01-22 Supergen, Inc. Pharmaceutical formulation
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
IL111184A (en) * 1993-10-08 2000-08-13 Farmarc Nederland B V Of Cito Crystalline inclusion complex of diclofenac with unsubstituted beta-cyclodextrin
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
IT1269578B (it) * 1994-04-22 1997-04-08 Chiesi Farma Spa Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base.
ZA959469B (en) * 1994-11-15 1996-05-15 South African Druggists Ltd Pharmaceutical composition
US5824668A (en) * 1996-11-07 1998-10-20 Supergen, Inc. Formulation for administration of steroid compounds
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
US6667056B2 (en) * 1997-07-23 2003-12-23 Chiesi Farmaceutici S.P.A. Pharmaceutical compositions containing an effervescent acid-base couple
IT1293764B1 (it) * 1997-07-23 1999-03-10 Chiesi Farma Spa Composizioni farmaceutiche sotto forma di compresse effervescenti contenenti un principio attivo instabile in presenza di acqua
FR2786395A1 (fr) * 1998-12-01 2000-06-02 Virbac Sa Compositions seches solubles en presence d'eau et evitant la reaction de maillard a l'etat sec, leur preparation et leurs applications
TWI242015B (en) 1999-11-29 2005-10-21 Akzo Nobel Nv 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
AU2002241611A1 (en) * 2000-12-04 2002-06-18 Sepracor, Inc. Orally-bioavailable formulations of fentanyl and congeners thereof
GB0205253D0 (en) * 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
DE60219609T2 (de) * 2002-06-17 2008-01-03 Chiesi Farmaceutici S.P.A. Prozess für die Vorbereitung von Piroxicam: Beta-Cyclodextrin Einschlusskomplexe
EP1582221A1 (en) * 2004-03-31 2005-10-05 Chiesi S.A. Pharmaceutical oral compositions with a taste masking effect
JP5091661B2 (ja) 2004-04-01 2012-12-05 ピエール ファーブル メディカモン 超臨界ｃｏ２と錯体相互作用剤を用いる方法によって得られる包接錯体
DE502004002443D1 (de) * 2004-04-15 2007-02-08 Helm Ag Verfahren zur Herstellung von freifliessenden, pulverförmigen Valsartan-Adsorbaten
US20060024922A1 (en) * 2004-07-27 2006-02-02 Da-Tung Wen Method for cutting wafer
AU2005268972A1 (en) * 2004-08-02 2006-02-09 Chiesi Farmaceutici S.P.A. A process for the preparation of a piroxicam: beta­cyclodextrin inclusion compound
FR2876910B1 (fr) 2004-10-21 2007-04-13 Pierre Fabre Medicament Sa Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction
US20070009532A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
US20070010487A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010465A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
US20070010486A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010485A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
GB0612695D0 (en) * 2006-06-27 2006-08-09 Univ Gent Process for preparing a solid dosage form
CL2007003876A1 (es) * 2007-12-28 2008-03-07 Univ De Concepcion Y Lab Andro Complejo de inclusion que esta formado por disulfiram y ciclodextrina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de la dependencia de alcohol y cocaina.
KR101383941B1 (ko) * 2012-03-09 2014-04-10 동아에스티 주식회사 피록시캄 또는 약제학적으로 허용되는 그의 염과 히알루론산 또는 약제학적으로 허용되는 그의 염의 안정한 액상 조성물 및 그 제조방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2827452A (en) * 1955-05-31 1958-03-18 Univ Minnesota Stabilization of materials
US3969338A (en) * 1971-03-15 1976-07-13 Institut National De La Recherche Agronomique Protein obtained from cakes of vegetable origin
HU184066B (en) * 1979-12-28 1984-06-28 Chinoin Gyogyszer Es Vegyeszet Plant growth regulating substance and process for preparing such compound
HU182217B (en) * 1980-10-17 1983-12-28 Chinoin Gyogyszer Es Vegyeszet Process for producing inclusive complexes of cyclodextrines and strong inorganic oxyacids
JPS5838250A (ja) * 1981-09-01 1983-03-05 Teikoku Chem Ind Corp Ltd 複合体
JPS58126810A (ja) * 1981-12-24 1983-07-28 Kaken Pharmaceut Co Ltd 抗炎症眼科用液剤およびその製法
JPS5920230A (ja) * 1982-07-19 1984-02-01 チバ−ガイギ−・アクチエンゲゼルシヤフト ピルプロフエン含有薬剤

Also Published As

Publication number Publication date
DK76085A (da) 1985-08-23
DK164911B (da) 1992-09-07
US4603123A (en) 1986-07-29
ES8504789A1 (es) 1985-05-01
ATE52263T1 (de) 1990-05-15
JPS60208979A (ja) 1985-10-21
DK164911C (da) 1993-01-18
IE850325L (en) 1985-08-22
BE900836A (fr) 1985-02-15
PH22075A (en) 1988-05-20
ES536909A0 (es) 1985-05-01
JPH0370705B2 (enExample) 1991-11-08
IT1196033B (it) 1988-11-10
DE153998T1 (de) 1986-04-10
DE3482041D1 (de) 1990-05-31
EP0153998A3 (en) 1987-01-14
NZ211114A (en) 1987-09-30
SG53690G (en) 1990-11-23
EP0153998B1 (en) 1990-04-25
AU550007B2 (en) 1986-02-27
ZA848156B (en) 1985-06-26
PT79997A (en) 1985-03-01
IT8419735A0 (it) 1984-02-22
KR870001960B1 (ko) 1987-10-23
KR850006133A (ko) 1985-10-02
AU3892385A (en) 1985-08-29
MY101374A (en) 1991-10-23
EP0153998A2 (en) 1985-09-11
PT79997B (en) 1987-01-13
DK76085D0 (da) 1985-02-19
IE58231B1 (en) 1993-08-11

Similar Documents

Publication Publication Date Title
CA1234106A (en) COMPOUNDS HAVING ANTIINFLAMMATORY ACTIVITY, OBTAINED BY COMPLEXATION WITH .beta.-CYCLODEXTRIN, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US8278437B2 (en) Hydroxypropyl-sulfobutyl-beta-cyclodextrin, the preparation method, the analytical method, and the pharmacutical application thereof
AU662986B2 (en) Novel inclusion complexes of clavulanic acid and of alkali salts thereof with hydrophilic and hydrophobic beta-cyclodextrin derivatives, a process for the preparation thereof and the use thereof
CA1119115A (en) Inclusion complex of cyclodextrin and indomethacin and a process for the preparation thereof
SU1757472A3 (ru) Способ получени комплексов включени 7-изопропоксиизофлавона
EP0422497B1 (en) Inclusion complexes with silybinin, their preparation and pharmaceutical compositions containing them
US4952565A (en) Inclusion complex of ibuproxam with beta-cyclodextrin, a process for preparing the same and a pharmaceutical preparation containing the same
KR100198046B1 (ko) 사이클로덱스트린과 니메설리드의 포접 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물
HK1006413B (en) Inclusion compounds of nimesulide with cyclodextrins
CN102718772A (zh) 一类羟喜树碱衍生物和其制剂的制备及临床应用
Singh et al. Physicochemical and Biological Studies of Inclusion Complex of Methotrexate with β‐Cyclodextrin
US4707472A (en) Cycloartenol ferulate/cyclodextrin complex
CN112110961A (zh) 葡萄糖酸钙中杂质的制备方法
EP0689844A1 (en) Complexes of vinpocetine formed with cyclodextrins, process for their preparation and pharmaceutical compositions containing them
US4272526A (en) Derivatives of chloral
CH676665A5 (enExample)
KR100673508B1 (ko) 신규 아세클로페낙의 아미노산염 및 이 염을 유효성분으로함유하는 약학적 제제
US4575509A (en) Water-soluble formulations of m-AMSA with pyroglutamic acid
CN113616813B (zh) 一种布洛芬与没食子酸改性磺丁基倍他环糊精钠的包合物
JPS6130551A (ja) ４−ビフエニリル酢酸−シクロデキストリン包接化合物
EP0449722B1 (fr) Nouveaux complexes de l'acide tiaprofénique ou de ses esters insolubles ou partiellement solubles avec les cyclodextrines ou leurs dérivés
CN102126983B (zh) 秋水仙碱衍生物及其制备方法和用途
LU83081A1 (fr) Compositions antitumeurs
EP0070049A1 (fr) Dérivé de l'acide acétylsalicylique ayant activité analgésique, antipyrétique, antiphlogistique et bronchosécrétolytique
JPS60172993A (ja) ジョサマイシンの（―）―シス―１，４―エポキシプロピルホスホネートおよびその製造法

Legal Events

Date Code Title Description
MKEX Expiry